A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Company to Ensure Orderly Transition from NASDAQ to OTC Market NEW YORK, Sept. 13, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that its Board of Directors...
NEW YORK, Sept. 01, 2017 -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
NEW YORK, Aug. 29, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, congratulates the team at the Medical University of Hannover Hospital on their performance of the...
Agreement Contingent upon Shareholder Vote in Favor of the Proposed Reverse Stock Split Voting Deadline Extended to September 7, 2017 NEW YORK, Aug. 28, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary...
NEW YORK, Aug. 22, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company") announced today that the deadline for its current Consent Solicitation (the "Consent Solicitation"), currently set to expire at 5:00 p.m. Eastern Time, on August 28, 2017, has been extended...
Company Comments on Consent Proposal; Provides Corporate UpdateNEW YORK, Aug. 8, 2017 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the...
NEW YORK, June 05, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company") announced today that its 2017 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled for June 5, 2017, was convened and adjourned, without any business being conducted. The Annual...
NEW YORK, May 09, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the three months ended March 31, 2017. Highlights for the first quarter...
NEW YORK, April 27, 2017 -- Delcath Systems, Inc. (Nasdaq:DCTH) (the "Company"), an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, President and Chief Executive...
NEW YORK, April 18, 2017 -- Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, commended Spire Southampton Hospital on the performance of over 100 percutaneous hepatic perfusion...